Wegovy and Zepbound are still hard to get. Knockoff versions from Noom, Ro, and others are filling in the gaps.

Hims & Hers shares tanked after regulators signaled new limits on the production of versions of weight-loss drugs.

GLP-1 RAs are being recommended on social media, raising questions about who can see the content and what the effects might ...

Andersen: The GLP-1 drugs, actually, they’ve been around a ... Take care. Here’s the new list of Morningstar’s top underpriced analyst picks to buy for the fourth quarter of 2024.

Food left in the stomach or stool left in the bowel can impede a doctor's ability to successfully perform an endoscopy or ...

According to the Journal, the GLP-1 "pricing fight" began in late 2023, when Lilly priced Zepbound at $1,060 per month, or 20% lower than Novo Nordisk's Wegovy. Analysts told the newspaper that prices ...

The anti-obesity drug market could one day be worth $100 billion. It's a massive opportunity in healthcare, and two companies that are leaders in that space today are Eli Lilly (NYSE: LLY) and ...

According to a recent article in the American Journal of Managed Care, the list price for GLP-1 drugs can range from $936 to $1,349 before insurance and other discounts. Costs are rising so fast ...

There is soaring demand for weight-loss drugs in the GLP-1 class, and the company will now sell it to certain professions for ...

GLP-1 based drugs are transforming the treatment of obesity and opening up new avenues for addressing heart disease, ...

Novo Nordisk recently said its supply of its GLP-1 drugs has improved ... get Ozempic in the U.S. The FDA continues to list these drugs in shortage, requiring manufacturers to prove they can ...

Research shows patients taking weight-loss drugs like Ozempic and Wegovy are more likely to have food left in the stomach or ...